Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 779 %
Debt-to-equity 19.7 %
Return On Equity -57.7 % -219%
Return On Assets -48.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.1M shares
Common Stock, Shares, Outstanding 33.1M shares +1924%
Entity Public Float 0 USD
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 33.1M shares +1932%
Weighted Average Number of Shares Outstanding, Diluted 33.1M shares +1932%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 63.9M USD +35.8%
General and Administrative Expense 29.4M USD +168%
Operating Income (Loss) -93.4M USD -55.6%
Nonoperating Income (Expense) 6.76M USD +1145%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -86.6M USD -46.7%
Net Income (Loss) Attributable to Parent -86.6M USD -29.7%
Earnings Per Share, Basic 17.5 USD/shares +92.8%
Earnings Per Share, Diluted 17.5 USD/shares +92.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 157M USD +343%
Other Assets, Current 3K USD -99.2%
Assets, Current 159M USD +310%
Property, Plant and Equipment, Net 1.18M USD +20.4%
Operating Lease, Right-of-Use Asset 8.44M USD -13.7%
Assets 174M USD +218%
Accounts Payable, Current 8.44M USD +218%
Liabilities, Current 26.8M USD +16.4%
Operating Lease, Liability, Noncurrent 6.79M USD -16.3%
Liabilities 34.5M USD +6.28%
Retained Earnings (Accumulated Deficit) -254M USD -51.7%
Stockholders' Equity Attributable to Parent 139M USD
Liabilities and Equity 174M USD +218%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD +19.1%
Net Cash Provided by (Used in) Financing Activities 88.7M USD
Net Cash Provided by (Used in) Investing Activities -193K USD
Common Stock, Shares Authorized 500M shares +2659%
Common Stock, Shares, Issued 33.1M shares +1891%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 73.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 160M USD +314%
Deferred Tax Assets, Valuation Allowance 62M USD +63.1%
Deferred Tax Assets, Gross 65.3M USD +54.7%
Operating Lease, Liability 8.9M USD -12.7%
Payments to Acquire Property, Plant, and Equipment 185K USD
Lessee, Operating Lease, Liability, to be Paid 10.8M USD -16.3%
Property, Plant and Equipment, Gross 1.79M USD +38.1%
Operating Lease, Liability, Current 2.11M USD +1.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.21M USD +2.51%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.15M USD +2.48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.95M USD -29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.26M USD +2.49%
Deferred Tax Assets, Operating Loss Carryforwards 21.9M USD +42.4%
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.32M USD +2.52%
Operating Lease, Payments 2.1M USD -26.7%
Deferred Tax Assets, Net of Valuation Allowance 3.37M USD -20.5%
Share-based Payment Arrangement, Expense 9.77M USD +334%
Interest Expense 174K USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares